124 related articles for article (PubMed ID: 9208874)
21. Divergence of binding, signaling, and biological responses to recombinant human hybrid IFN.
Hu R; Bekisz J; Hayes M; Audet S; Beeler J; Petricoin E; Zoon K
J Immunol; 1999 Jul; 163(2):854-60. PubMed ID: 10395679
[TBL] [Abstract][Full Text] [Related]
22. Mapping human interferon-alpha (IFN-alpha 2) binding determinants of the type I interferon receptor subunit IFNAR-1 with human/bovine IFNAR-1 chimeras.
Goldman LA; Cutrone EC; Dang A; Hao X; Lim JK; Langer JA
Biochemistry; 1998 Sep; 37(37):13003-10. PubMed ID: 9737881
[TBL] [Abstract][Full Text] [Related]
23. Binding and activity of all human alpha interferon subtypes.
Lavoie TB; Kalie E; Crisafulli-Cabatu S; Abramovich R; DiGioia G; Moolchan K; Pestka S; Schreiber G
Cytokine; 2011 Nov; 56(2):282-9. PubMed ID: 21856167
[TBL] [Abstract][Full Text] [Related]
24. Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions.
Pfeffer LM; Wang C; Constantinescu SN; Croze E; Blatt LM; Albino AP; Nanus DM
J Urol; 1996 Nov; 156(5):1867-71. PubMed ID: 8863634
[TBL] [Abstract][Full Text] [Related]
25. Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi Burkitt's lymphoma cells.
Yamaoka T; Kojima S; Ichi S; Kashiwazaki Y; Koide T; Sokawa Y
J Interferon Cytokine Res; 1999 Dec; 19(12):1343-9. PubMed ID: 10638703
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of antiviral activity between FeIFN-omega and FeIFN-alpha].
Wang H; Jia X; Yang L; Sun L; Wang H; Liu W
Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1556-60. PubMed ID: 19160837
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the alpha subunit of the IFN-alpha receptor. Evidence of N- and O-linked glycosylation and association with other surface proteins.
Platanias LC; Pfeffer LM; Cruciani R; Colamonici OR
J Immunol; 1993 Apr; 150(8 Pt 1):3382-8. PubMed ID: 8468477
[TBL] [Abstract][Full Text] [Related]
28. Three-dimensional models of interferon-alpha subtypes IFN-con1, IFN-alpha8, andIFN-alpha1 derived from the crystal structure of IFN-alpha2b.
Walter MR
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-52-S9-62. PubMed ID: 9208873
[TBL] [Abstract][Full Text] [Related]
29. Human type I interferons: structure and function.
Kontsek P
Acta Virol; 1994 Dec; 38(6):345-60. PubMed ID: 7793359
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of a single amino acid substitution at position 79 of human IFN-α2b in interferon-receptor assembly and activity.
Talebi S; Saeedinia A; Zeinoddini M; Ahmadpour F; Sadeghizadeh M
Prep Biochem Biotechnol; 2019; 49(8):735-743. PubMed ID: 31135267
[TBL] [Abstract][Full Text] [Related]
31. Differential Biological Activities of Swine Interferon-α Subtypes.
Zanotti C; Razzuoli E; Crooke H; Soule O; Pezzoni G; Ferraris M; Ferrari A; Amadori M
J Interferon Cytokine Res; 2015 Dec; 35(12):990-1002. PubMed ID: 26447602
[TBL] [Abstract][Full Text] [Related]
32. Dose-Dependent Differences in HIV Inhibition by Different Interferon Alpha Subtypes While Having Overall Similar Biologic Effects.
Schlaepfer E; Fahrny A; Gruenbach M; Kuster SP; Simon V; Schreiber G; Speck RF
mSphere; 2019 Feb; 4(1):. PubMed ID: 30760614
[TBL] [Abstract][Full Text] [Related]
33. [Interferons--biologic principles and clinical uses].
Jacobsen H; Kirchner H
Klin Padiatr; 1985; 197(4):263-7. PubMed ID: 3930830
[TBL] [Abstract][Full Text] [Related]
34. Balancing the pharmacokinetics and pharmacodynamics of interferon-α2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy.
Zhao HL; Xue C; Du JL; Ren M; Xia S; Liu ZM
Mol Pharm; 2012 Mar; 9(3):664-70. PubMed ID: 22224503
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the murine alpha interferon gene family.
van Pesch V; Lanaya H; Renauld JC; Michiels T
J Virol; 2004 Aug; 78(15):8219-28. PubMed ID: 15254193
[TBL] [Abstract][Full Text] [Related]
36. Comparative antiproliferative and receptor binding activities of interferons alpha and beta on lymphoblastoid and melanoma cells.
Hertzog PJ; Johns TG; Callister KA; Dinatale A; Linnane AW
Biochem Int; 1990 Dec; 22(6):1095-102. PubMed ID: 2151021
[TBL] [Abstract][Full Text] [Related]
37. Evidence for multiple binding sites for several components of human lymphoblastoid interferon-alpha.
Hu R; Gan Y; Liu J; Miller D; Zoon KC
J Biol Chem; 1993 Jun; 268(17):12591-5. PubMed ID: 8509399
[TBL] [Abstract][Full Text] [Related]
38. Complementation of the interferon alpha response in resistant cells by expression of the cloned subunit of the interferon alpha receptor. A central role of this subunit in interferon alpha signaling.
Colamonici OR; Porterfield B; Domanski P; Constantinescu S; Pfeffer LM
J Biol Chem; 1994 Apr; 269(13):9598-602. PubMed ID: 8144546
[TBL] [Abstract][Full Text] [Related]
39. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon.
Blatt LM; Davis JM; Klein SB; Taylor MW
J Interferon Cytokine Res; 1996 Jul; 16(7):489-99. PubMed ID: 8836913
[TBL] [Abstract][Full Text] [Related]
40. Differential neutralizing activity of human antibodies in interferon antiviral and natural killer cell bioassays.
Thurmond LM; Reese MJ
J Interferon Cytokine Res; 1997 Oct; 17(10):619-23. PubMed ID: 9355963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
